Seattle-based startup Immunexpress is set to complete an FDA de novo filing for its SeptiCyteLab sepsis test that it says tells the physician the probability the patient has sepsis within a few hours. That would be a big step up from current sepsis diagnostics that can take over a day to complete and often provide no useful information, the firm says.
The company hopes FDA will clear SeptiCyte Lab by the end of 2015 with a market launch set for the second half of 2016. Immunexpress is also working on a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?